Healthcare / BiotechnologyNYSE
$3.40
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-124.7M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$432M
P/E
N/A
•EV/EBITDA
N/A
•ROE
76.7%
↑Gross Margin
92.9%
↑Debt/Equity
-0.63
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-27.1%
FCF CAGR
—
FCF margin
-173.8%
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $81.4M · net income $-142.6M · FCF $-141.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $81.4M | $81.4M | $70.8M | $69.6M | $209.9M |
| Net Income | $-142.6M | $-142.6M | $-157.8M | $-240.1M | $-157.1M |
| EBITDA | $-88.1M | $-88.1M | $-102.6M | $-145.8M | $-107.7M |
| EPS | — | — | -1.62 | -2.94 | -1.99 |
| Gross Margin | 92.9% | 92.9% | 91.6% | 96.4% | 98.4% |
| Operating Margin | -131.8% | -131.8% | -182.9% | -237.3% | -58.6% |
| Net Margin | -175.3% | -175.3% | -222.8% | -345.1% | -74.9% |
| Balance Sheet | |||||
| Debt/Equity | -0.63 | -0.63 | -0.61 | -0.84 | 1.48 |
| Current Ratio | 4.09 | 4.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-141.4M | $-141.4M | $-124.7M | $-121.9M | $-139.0M |
| Returns | |||||
| ROE | 76.7% | 76.7% | 77.9% | 161.9% | -197.8% |
| Valuation | |||||
| P/B | — | — | — | — | 3.49 |
| Growth & Yield | |||||
| Revenue Growth | 14.9% | 14.9% | 1.8% | -66.9% | — |
| EPS Growth | — | — | 44.9% | -47.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.62 → n/d
Residual
+10.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.